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Abstract
A strategy for the light-activated release of bioactive compounds (BODIPY, colchicine, paclitaxel, 
and methotrexate) from membrane-enclosed depots is described. We have found that membrane 
permeable bioagents can be rendered membrane impermeable via covalent attachment to 
cobalamin (Cbl) through a photo-cleavable linker. These Cbl-bioagent conjugates are imprisoned 
within lipid-enclosed compartments in the dark, as exemplified by their retention in the interior of 
erythrocytes. Subsequent illumination drives the secretion of the bioactive species from red blood 
cells. Photo-release is triggered by wavelengths in the red, far red and near IR, which can be pre-
assigned by affixing a fluorophore with the desired excitation wavelength to the Cbl-bioagent 
conjugate. Pre-assigned wavelengths allow different biologically active compounds to be 
specifically and unambiguously photo-released from common carriers.
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Membrane-impermeable, photo-responsive, conjugates have been developed that can be inserted 
into and retained by membrane-enclosed compartments. Illumination generates a membrane 
permeable biologically active agent, which is rapidly secreted. Furthermore, the wavelength of 
photo-release can be unambigously pre-assigned, enabling the specific discharge of different 
bioagents from a common carrier.
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Light serves as a stimulus for nearly all forms of life, as exemplified by phototropism,[1] 
displayed by plants and insects, and the circadian clock,[2] which is found in organisms that 
range from cyanobacteria to humans. Light, which can be applied with exquisite spatial and 
temporal precision, possesses photophysical properties (intensity, wavelength) that are 
readily modulated. These attributes, when applied in conjunction with chemically and 
biologically engineered photo-responsive molecules, have been used to probe and perturb 
biological phenomena in cells, tissues, and organisms. A wide variety of bioactive 
compounds have been converted into light-responsive derivatives by either (1) modifying 
essential functional groups with photocleavable moieties or (2) introducing light-triggered 
configurational switches that reversibly convert the inactive and active forms of the 
bioagent.[3] By contrast, genetically encoded “optogenetic” proteins are typically 
constrained or transferred to specific intracellular sites required for their mechanism of 
action.[4] Is the opposite possible? Can bioagents be restricted to specific inert compartments 
and then use light to trigger their release? The advantage of this approach is that it is not 
necessary to impair, alter, or modify the innate biochemical activity of the agent under study.
We recently reported that vitamin B12 (cobalamin; “Cbl”) serves as a molecular platform for 
the photo-release of drugs due to the presence of an extraordinary photo-cleavable Co-C 
bond[5].[6] B12 is not membrane permeable, but rather is transported into cells via a 
sophisticated protein carrier, receptor-mediated, endosome-dependent mechanism.[7] We 
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wondered whether Cbl-bioagent conjugates might retain the membrane impermeability 
properties of the parent B12 and thus could be ensconced within lipid-enclosed 
compartments until needed. Previously, we’ve shown that the light responsiveness of Cbl 
conjugates can be tuned to specific wavelengths deep into the red, far red, and near IR.[6b] 
These wavelengths penetrate tissue more effectively than UV and short visible wavelengths, 
a decided advantage under in vivo conditions.[8] With these features in mind, we chose the 
interior of erythrocytes as a membrane enclosed environment to explore the conjecture that 
illumination can be used to control the secretion of biologically active compounds (Figure 
1). We anticipated that loading Cbl-bioagent conjugates into the interior of erythrocytes 
would be straightforward since red blood cells swell upon exposure to a hypotonic buffer, 
creating pores in the plasma membrane.[9] Subsequent resealing with an isotonic buffer 
should entomb the anticipated membrane impermeable Cbl-bioagent in the erythrocyte.
BODIPY®650 (BODIPY) is an extensively employed membrane permeable fluorescent 
dye.[10] We prepared the Cbl-BODIPY conjugate (2, Scheme 1) from 1a (where R = NH2) 
and the corresponding BODIPY carboxylic acid derivative. Photolysis of 2 furnished the 
anticipated product (scission at the Co-C bond) as confirmed by LC-MS (Figure S1). 
Erythrocytes were loaded with 2 using a modified hypotonic/isotonic literature protocol 
(SI).[9] Subsequent washing of the erythrocytes with serum-containing cell culture medium 
removed free Cbl-BODIPY that had not been installed within the erythrocyte interior 
(Figures S2 - S4). Light-triggered (660 nm; LED power = 3.30 ± 0.02 mW/cm2; 0 – 5 min) 
BODIPY release was monitored from loaded erythrocytes in 10% hematocrit solutions. The 
time dependent release of BODIPY from 2-loaded erythrocytes was quantified by spinning 
down the blood cells after illumination and measuring the fluorescence in the supernatant 
(released BODIPY) and the pellet (retained BODIPY; Figures 2, S5). Control experiments 
were performed under identical conditions in the dark. As anticipated, Cbl-BODIPY 2 is 
retained by erythrocytes in the dark, with only a negligible amount of BODIPY present in 
the supernatant (<1%) as a percentage of total Cbl-BODIPY loaded (Figure 2). By contrast, 
660 nm illuminated (3 min) samples display robust BODIPY release (80.7 ± 6.4%). Various 
illumination times were explored and we found that maximal Cbl-BODIPY photolysis 
occurs at 3 min of illumination (Figure S5).
We subsequently prepared several Cbl conjugates containing methotrexate (MTX; 3), 
colchicine (COL; 4) and paclitaxel (PTX; 5). These green light-sensitive Cbl-bioactives were 
prepared by coupling Cbl-propylamine (1a) to MTX and succinyl-PTX (Scheme 1). By 
contrast, Cbl-butyrate (1b) was appended to the free amine of the deacetylated form of 
colchicine (Schemes S1 – S3; Figures S6 – S8). We confirmed (LC-MS) that these species 
suffer photolysis via scission of the Co-C bond (Figures S9 – S11). These species were 
introduced into erythrocytes using the hypotonic-loading protocol described in the previous 
paragraph. The bioactive agents were subsequently released from erythrocytes via 
illumination at 525 nm, and their biological impact on co-plated HeLa cells monitored. The 
effect of photo-released MTX on HeLa cells was assessed by the “CETSA assay” (Figures 
3, S12).[11] Following exposure to MTX-containing erythrocytes, HeLa cells were exposed 
to elevated temperatures, lysed, and the lysate centrifuged to separate soluble proteins from 
their insoluble counterparts. In the absence of MTX, elevated temperatures denature 
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dihydrofolate reductase (DHFR) rendering it insoluble and poorly observable by western 
blot. By contrast, MTX-bound DHFR is more resistant to heat-induced denaturation. Only a 
small amount of DHFR is detected when HeLa cells are incubated in the dark with 3 
embedded within erythrocytes. On the other hand, illumination results in MTX release as 
evidenced by the dramatic increase in stabilized DHFR (Figure 3A–C). Likewise, 525 nm-
illuminated erythrocytes containing Cbl-COL induced COL take-up by HeLa cells. In the 
absence of COL, microtubules extend from the nucleus to the cell surface (Figure 3D). By 
contrast, upon COL photo-release, microtubule polymerization is blocked, leading to 
shortened and disrupted microtubule morphology (Figure 3E, S13). Finally, erythrocytes 
conveying Cbl-PTX released an active paclitaxel derivative upon 525 nm exposure, which 
stabilizes microtubules against depolymerization as revealed by coalescence (Figures 3F–G, 
S14).
Having established the methodology for the encapsulation and on-command light-triggered 
release of bioactive compounds from erythrocytes, we sought to extend the wavelength 
window of release into the 650 – 800 nm realm. We’ve previously shown that Co-C 
photolysis can be induced by red, far red, or near IR light using Cbl derivatives possessing 
appended long wavelength, light-harvesting fluorophores.[6b] Given the unique excitation 
wavelengths of individual fluorophores, we investigated whether specific agents could be 
released from erythrocytes in a wavelength-designated fashion.
Red light-sensitive analogs of Cbl-MTX and Cbl-PTX were prepared using Cy5 as an 
appended long wavelength antenna (6 – 7; λex = 660 nm, Scheme 2). We also synthesized a 
corresponding near IR responsive analog of Cbl-COL by affixing “FL800” to the ribose ring 
(8; λex = 780 nm; Schemes 2 and S4, Figure S15). The synthetic routes to Cy5-Cbl-MTX 6, 
Cy5-Cbl-PTX 7 and FL800-Cbl-COL 8 employ compounds 1a and 1b as the starting 
materials. In addition, the ribose 5′-OH was activated (1,1′-carbonyl-di-triazole) and 
subsequently reacted with ethylenediamine, to provide a handle upon which the long 
wavelength fluorophores are secured (Schemes S5 – S11; Figures S16 – S18). All three 
fluorophore-Cbl-bioactive conjugates furnish the photolyzed Co-C cleaved products at their 
assigned wavelengths (Figures S19 – S21). The phototherapeutic agents were encapsulated 
in erythrocytes via exposure to a hypotonic solution. In contrast to the Cbl derivatives 3 – 5, 
analogs 6 – 8 respond to wavelengths beyond which the Cbl ring absorbs light. Both 
erythrocyte-embedded Cy5-Cbl-MTX 6 and Cy5-Cbl-PTX 7 release their bioactive cargo at 
660 nm. When co-cultured with HeLa cells, light-triggered MTX secretion from 
erythrocytes was confirmed by the CETSA assay and PTX release was demonstrated by 
microtubule immunostaining (Figures S22 – S23). In addition, FL800-Cbl-COL 8 is 
designed to respond to near IR wavelengths. 780 nm exposure of erythrocytes containing 
FL800-Cbl-COL triggered COL secretion and depolymerization of HeLa cell microtubules 
(Figure S24).
Given the fact that the long wavelength excitation spectra of the BODIPY and FL800 
fluorophores in this study are non-overlapping (Figure S25) we investigated the orthogonal 
light-triggered secretion of bioactive compounds by simply modulating the wavelength of 
illumination. We considered two possible loading strategies: (1) Cbl derivatives co-loaded 
into the same erythrocytes and (2) Cbl derivatives loaded in different erythrocytes and 
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subsequently mixed to create a single pool of blood cells. Both possibilities were explored 
using the 650 nm sensitive Cbl-BODIPY 2 and the 780 nm responsive FL800-Cbl-COL 8. 
Both approaches furnished erythrocyte-encapsulated Cbl-bioagent conjugates that 
differentially release their cargo in response to orthogonal wavelength-embedded commands 
(Figures 4, S26 – S28). For example, erythrocytes loaded with both 2 and 8, when exposed 
to 660 nm, selectively release BODIPY, which is taken up by HeLa cells (Figure 4A). By 
contrast, 780 nm exposure triggers COL discharge and subsequent structural disruption of 
HeLa microtubules (Figure 4B). Both compounds resist release from erythrocytes when 
illuminated at non-absorbing wavelengths (Figures S126, S28). Analogous studies were 
performed with erythrocytes that were separately loaded with 2 or 8 and subsequently mixed 
into a single pool (Figures S27 – S28). These results confirm wavelength-specified photo-
secretion of specific bioagents from membrane-delimited compartments.
In conclusion, we’ve demonstrated that long wavelength responsive bioactive species can be 
constructed by appending membrane impermeable Cbl via a photo-cleavable Co-C bond. We 
anticipate that this strategy could prove applicable to other membrane-enclosed 
compartments, such as endosomes, the cytoplasm, or various organelles in conjunction with 
robust delivery moieties. These studies are in progress. In addition, we’ve shown that photo-
secretion can be triggered by preassigned wavelengths, an easily modulated photophysical 
property of light. Finally, it has not escaped our attention that on-command selective release 
of therapeutic agents from biocompatible delivery vehicles[12] offers a strategy that 
addresses many of the challenges encountered by drug targeting to diseased sites.
Experimental Section
See the online Supporting Information for Materials and Methods and Supporting Figures 
and Schemes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Light-mediated release of compartmentalized light-responsive compounds. Membrane 
impermeable Cbl-bioagents are retained inside erythrocytes. Photolysis produces membrane 
permeable bioagents that can escape the cell.
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The percentage of BODIPY retained by (pellet; □) and released from (supernatant; ■) 
erythrocytes as a function of total loaded Cbl-BODIPY under dark and 660 nm conditions. 
BODIPY is retained by erythrocytes maintained in the dark. By contrast, 80.7 ± 6.4% of 
BODIPY is released upon a 3 min exposure to a 660 nm LED array. Compare with Figure 
S5.
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Cell-based assays for internalized phototherapeutic release at 525 nm. (A) DHFR western 
blot (CETSA assay) of HeLa cells incubated with 3-loaded erythrocytes in the dark or (B) 
following exposure to 525 nm light. (C) Quantification of western blot optical density is 
consistent with photo-release of MTX. (D) Immunostained HeLa cell microtubules 
incubated with 4-loaded erythrocytes in the dark or (E) exposed to 525 nm light. Structurally 
compromised microtubules are consistent with COL photo-release. (F) Immunostained HeLa 
cell microtubules incubated with 5-loaded erythrocytes in the dark or (G) exposed to 525 nm 
light. Condensed microtubules are consistent with PTX photo-release. Scale bars = 10 μm.
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Orthogonal release of 660 nm-sensitive 2 and 780-sensitive 8 from erythrocytes and uptake 
by HeLa cells. Left columns show fluorescence of BODIPY650 in HeLa cells and right 
columns displays HeLa cell microtubules. (A) Erythrocytes exposed to 660 nm light release 
BODIPY, which is taken up by HeLa cells as demonstrated by red fluorescence. By contrast, 
(B) no COL is released under these conditions as demonstrated by intact microtubules. (C–
D) Erythrocytes exposed to 780 nm light. Under these circumstances, (C) no BODIPY is 
released. (D) However, COL is delivered to HeLa cells as evidenced by the presence of 
compromised microtubules. Results from experiments conducted in the dark or 
simultaneously exposed to both 660 and 780 nm are furnished in Fig. S27. Scale bars = 10 
microns.
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Cbl-Drug conjugates prepared from 1 (where R = NH2 or CO2H): Cbl-BODIPY (2), Cbl-
MTX (3), Cbl-COL (4), and Cbl-PTX (5).
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Cy5 derivatives of Cbl-MTX (6 where R = MTX) and Cbl-PTX (7 where R = PTX) and 
FL800 derivative of Cbl-COL (8 where R = COL).
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